Find Clinical Trial

Phase I/II, international, multicentre, open-label, non-randomised, non-comparative, study evaluating the safety, tolerability and clinical activity of intravenously administered S64315, a selective Mcl-1 inhibitor, in combination with azacitidine in patients with acute myeloid leukaemia (AML)


← Back
Study Phase

Phase 1-2

Therapeutic Area

Cancers

IndicationBlood cancer
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

S064315

Active Substance CodeS064315
Protocol CodeCL1-64315-004
EudraCT Code2019-004896-38
NCT CodeNCT04629443




Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2020 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility